Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes

American Journal of Therapeutics

Volumn 12, Issue 6, 2005, Pages 481-490

  Aly, Theresa ^a   Devendra, Devasenan ^a   Eisenbarth, George S ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Clinical trial; Immunotherapy; Prevention; Type 1 diabetes

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIHISTAMINIC AGENT; AUTOANTIBODY; AZATHIOPRINE; BCG VACCINE; CASEIN HYDROLYSATE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; GALACTOSYLCERAMIDE; GLUCOCORTICOID; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GLUTEN; INSULIN; INSULINOMA ASSOCIATED 2 AUTOANTIBODY; INTERLEUKIN 2 MONOCLONAL ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OKT 3; OKT 4; PARVOVIRUS VECTOR; PROINSULIN; PROTEINASE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY DETECTION; BCG VACCINATION; CELL DESTRUCTION; CLINICAL TRIAL; CONFERENCE PAPER; DIET; FEVER; GENETIC MARKER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; ISOGRAFT; LYMPHADENOPATHY; MOUTH ULCER; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PLASMAPHERESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RASH; VIRAL GENE THERAPY;

ANIMALS; AUTOANTIBODIES; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MICE; NIACINAMIDE; RANDOMIZED CONTROLLED TRIALS; RATS;

EID: 28044473162     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000178782.97413.79     Document Type: Conference Paper

References (57)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221-229.
2. Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2ab, Gadab, IAA, ICA) in type 1 diabetes: Combinatorial islet autoantibody workshop. Diabetes. 1998;47:1857-1866.
3. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med. 1999;5:601-604.
4. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381-389.
5. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996;45:926-933.
6. Krischer JP, Cuthbertson DD, Yu L, et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab. 2003;88:103-108.
7. Chase HP, Garg SK, Butler-Simon N, et al. Prediction of the course of pre-type I diabetes. J Pediatr. 1991;118:838-841.
8. Smith C. Concordance in twins: methods and interpretation. Am J Hum Genet. 1974;26:454-466.
9. Trudeau JD, Kelly-Smith C, Verchere CB, et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest. 2003;111:217-223.
10. Chatenoud L. Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation. Diabetologia. 2001;44:521-536.
11. Wegmann DR, Eisenbarth GS. It's insulin. J Autoimmun. 2000;15:286-291.
12. Bluestone JA, Matthews J. The Immune Tolerance Network: tolerance at the crossroads. Philos Trans R Soc Lond B Biol Sci. 2001;356:773-776.
13. Belghith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med. 2003;9:1202-1208.
14. Chase HP, Hayward AR, Eisenbarth GS. Clinical trials for the prevention of type 1 diabetes. In: Type 1 Diabetes: Molecular, Cellular and Clinical Immunology. February 24, 2004. Available at: http://www.uchsc.edu/misc/diabetes/ eisenbook.html. Accessed March 15, 2004.
15. Moriyama H, Paronen J, Liu E, et al. Testing the hypothesis that the insulin 1 gene is essential for diabetogenesis and knockout of insulin 2 gene accelerates diabetes in NOD mice. Diabetes Metab Res Rev. 2002;18(Suppl 4):S26.
16. Paronen J, Moriyama H, Abiru N, et al. Establishing insulin 1 and insulin 2 knockout congenic strains on NOD genetic background. Ann N Y Acad Sci. 2003;1005:205-210.
17. Steptoe RJ, Ritchie JM, Harrison LC. Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J Clin Invest. 2003;111:1357-1363.
18. Song S, Goudy K, Campbell-Thompson M, et al. Recombinant adeno-associated virus-mediated alpha-1 anti-trypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther. 2004;11:181-186.
19. Liu E, Moriyama H, Paronen J, et al. Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse. J Autoimmun. 2003;21:213-219.
20. Chatenoud L, Thervet E, Primo J, et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A. 1994;91:123-127.
21. Harada M, Kishimoto Y, Makino S. Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes. 1990;8:85-90.
22. Chikuma S, Bluestone JA. CTLA-4 and tolerance: the biochemical point of view. Immunol Res. 2003;28:241-253.
23. Hutton JC, Eisenbarth GS. A pancreatic {beta}-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes. Proc Natl Acad Sci U S A. 2003;100:8626-8628.
24. Norris JM, Beaty B, Klingensmith G, et al. Lack of association between early exposure to cow's milk protein and b-cell autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY). JAMA. 1996;276:609-614.
25. Carel J-C, Boitard C, Eisenbarth G, et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type I diabetic children. J Autoimmun. 1996;9:739-745.
26. LeDoux SP, Hall CR, Forbes PM, et al. Mechanisms of nicotinamide and thymidine protection from alloxan and streptozotocin toxicity. Diabetes. 1988;37:1015-1019.
27. Uchigata Y, Yamamoto H, Nagai H, et al. Effect of poly(ADP-ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis. Diabetes. 1983;32:316-318.
28. Kolb H, Burkart V, Appels B, et al. Essential contribution of macrophages to islet cell destruction in vivo and in vitro. J Autoimmun. 1990;3(Suppl 1):117-120.
29. Elliott RB, Chase HP, Pilcher CC, et al. Effect of nicotinamide in preventing diabetes (IDDM) in children. J Autoimmun. 1990;3:61A.
30. Gale EA. Theory and practice of nicotinamide trials in pre-type 1 diabetes. J Pediatr Endocrinol Metab. 1996;9:375-379.
31. Devendra D, Eisenbarth GS. Interferon alpha a potential link in the pathogenesis in the viral induced type 1 diabetes and autoimmunity. Clin Immunol. 2004;111:225-233.
32. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294:1540-1543.
33. Sobel DO, Newsome J, Ewel CH, et al. Poly I:C induces development of diabetes mellitus in BB rat. Diabetes. 1992;41:515-520.
34. Deleted in proof.
35. Chuntharapai A, Lai J, Huang X, et al. Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine. 2001;15:250-260.
36. Brod SA, Atkinson M, Lavis VR, et al. Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes. J Interferon Cytokine Res. 2001;21:1021-1030.
37. Pozzilli P. The DPT-1 trial: a negative result with lessons for future type 1 diabetes prevention. Diabetes Metab Res Rev. 2002;18:257-259.
38. Kupila A, Muona P, Simell T, et al. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia. 2001;44:290-297.
39. Feutren G, Assan G, Karsenty G, et al. Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986;2:119-124.
40. Dupre J, Stiller CR, Gent M, et al. Clinical trials of cyclosporin in IDDM. Diabetes Care. 1988;11(suppl 1):37-44.
41. DeFilippo G, Carel JC, Boitard C, et al. Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes. 1996;45:101-104.
42. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692-1698.
43. Qin HY, Singh B. BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J Autoimmun. 1997;10:271-278.
44. Allen HF, Klingensmith GJ, Jensen P, et al. Effect of BCG vaccination on new-onset insulin-dependent diabetes mellitus: a randomized clinical study. Diabetes Care. 1998;22:1703-1707.
45. Alleva DG, Crowe PD, Jin L, et al. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest. 2001;107:173-180.
46. Abiru N, Maniatis AK, Yu L, et al. Peptide and MHC specific breaking of humoral tolerance to native insulin with the B:9-23 peptide in diabetes prone and normal mice. Diabetes. 2001;50:1274-1281.
47. Alleva DG, Gaur A, Jin L, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002;51:2126-2134.
48. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A. 1996;93:956-960.
49. Liu E, Moriyama H, Abiru N, et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest. 2002;110:1021-1027.
50. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet. 2001;358:1749-1753.
51. Bowman M, Atkinson MA. Heat shock protein therapy fails to prevent diabetes in NOD mice. Diabetologia. 2002;45:1350-1351.
52. Tisch R, Wang B, Atkinson MA, et al. A glutamic acid decarboxylase 65-specific Th2 cell clone immunoregulates autoimmune diabetes in nonobese diabetic mice. J Immunol. 2001;166:6925-6936.
53. Tisch R, Wang B, Serreze DV. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol. 1999;163:1178-1187.
54. Vu MD, Qi S, Xu D, et al. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation. 1998;66:1575-1580.
55. Hao L, Chan S-M, Lafferty KJ. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann N Y Acad Sci. 1993;696:328-332.
56. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-238.
57. Hirshberg B, Rother KI, Digon BJ III, et al. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care. 2003;26:3288-3295.